Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Latanoprost controlled release - Peregrine Ophthalmic

Next Previous
Drug Profile

Latanoprost controlled release - Peregrine Ophthalmic

Alternative Names: Latanoprost extended release -Preregrine Ophthalmic; Latanoprost liposomal - Peregrine Ophthalmic; LIPOLAT; liposomal latanoprost - Peregrine Ophthalmic; POLAT 001

Latest Information Update: 11 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peregrine Ophthalmic
  • Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension
  • Phase I Subcutaneous fat disorders

Most Recent Events

  • 18 Nov 2024 Peregrine Ophthalmic completes a phase I clinical trials in Subcutaneous fat disorders (In volunteers) in USA (Transdermal) (NCT05935527)
  • 28 Apr 2023 Phase-I clinical trials in Subcutaneous fat disorders (In volunteers) in USA (Transdermal) (NCT05935527)
  • 02 Jan 2023 No development reported - Phase-II for Subcutaneous fat disorders (In adults) in Thailand (Transdermal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top